Business Description

Lupin Ltd (Lupin) undertakes the manufacture and marketing of generic and branded pharmaceutical products, and active pharmaceutical ingredients (APIs). The company offers these drugs in various formulations such as solid, semi-solid and liquid. It is one of the leading and fasting growing companies. Its product portfolio is focused on various therapeutic areas such as cardiovascular, diabetics, asthma, respiratory diseases, pediatrics, oncology, immunology, metabolic disorders, central nervous system, gastrointestinal, tuberculosis, infections and non-steroidal anti-inflammatory drugs. The company is also focused on oral, ophthalmic, dermatology and inhalation product development. The company reports its operations under single segment, namely, Pharmaceuticals. Lupin’s business includes formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products. The company’s global formulations business develops and delivers a broad range of branded and generic formulations, biotechnology products and APIs worldwide. Lupin specializes in the diabetology, cardiovascular, pediatric, asthma, gastrointestinal, central nervous system (CNS) therapeutics, anti-infectives, anti-TB and nonsteroidal anti-inflammatory drugs (NSAID) space. Principal markets of formulations business include India, the US, Japan, Europe, South Africa, Philippines, and Australia. The business operates 18 manufacturing facilities worldwide. Its APIs products include antibiotics for cephalosporin and non-systemic gastro-intestinal; Anti-B; cardiovascular products including anti-hypertensive, anti-hyperlipidemic and anti-thrombotic, for CNS including anti-convulsant, anti-Parkinson and neuropathic pain agent; as well as for analgesics and anti-gout. The company's biotechnology (biotech) division focuses on manufacturing high quality biologics and biosimilars. It has a pipeline of ten biosimilars in various stages of clinical development. Lupin commercialized oncology products: Lupifil and Lupifil-P, biosimilars for molecules Filgrastim and Peg-Filgrastim in India. It is developing biosimilar for Etanercept under the brand Enbrel. Lupin’s advanced drug delivery systems business has developed various platforms including, bio-adhesive / gastro-retentive extended release systems, laser-drilled extended release systems, bioavailability enhancement systems based on solubilization and nano-particle technology, matrix or reservoir based release systems, and taste masking technologies for solid and liquid orals. The company operates manufacturing facilities in India, Japan, the US, Brazil and Mexico. It sells its products to over 100 countries in the US, the UK, Europe, Germany, India, Japan, South Africa, Philippines, and Australia through a network of international subsidiaries and a Joint Venture in Japan. Geographically, the company generates its revenue from four regions, namely, India, the US, Japan, and other.

R&D Overview

The company focuses its research and development programs on the discovery of new biosimilars in the areas of pain, inflammation, metabolic and endocrine diseases, auto immune diseases, central nervous system disorders, oncology and infectious diseases. These advanced drug delivery platforms enable the company to produce value added generic and branded pharmaceuticals. The company has a strong portfolio of products for including 457 ANDAs and four NDAs which have been approved by the US FDA. The company operates, 13 US FDA inspected manufacturing units; 15 manufacturing sites; and 15 state of the art R&D facilities worldwide. In FY2022 Lupin’s expenditure on R&D amounted to INR14,023.6 million, which as a percentage stood at 8.5%.




Geographical Segments

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Get started with Company Analytics for access to geographical segment data Get started with Company Analytics for access to geographical segment data Learn More
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer